|
C8ORF41 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62581059726108E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.62563362350011E-14 |
| Normal-vs-Stage2 |
3.97910000000667E-05 |
| Normal-vs-Stage3 |
5.57220936059366E-13 |
| Normal-vs-Stage4 |
5.36171107512473E-12 |
| Stage1-vs-Stage2 |
1.458200E-01 |
| Stage1-vs-Stage3 |
5.907600E-02 |
| Stage1-vs-Stage4 |
1.618190E-02 |
| Stage2-vs-Stage3 |
1.751540E-02 |
| Stage2-vs-Stage4 |
5.535700E-03 |
| Stage3-vs-Stage4 |
4.206000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.55431223447522E-15 |
| Normal-vs-AfricanAmerican |
2.04010000000032E-05 |
| Normal-vs-Asian |
1.05659999638519E-08 |
| Caucasian-vs-AfricanAmerican |
8.167800E-01 |
| Caucasian-vs-Asian |
7.137200E-01 |
| AfricanAmerican-vs-Asian |
9.742600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.60076421404665E-13 |
| Normal-vs-Female |
1.65345515057425E-12 |
| Male-vs-Female |
1.920000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.83275616905121E-12 |
| Normal-vs-Age(41-60Yrs) |
2.49367193561056E-12 |
| Normal-vs-Age(61-80Yrs) |
1.12080345004983E-11 |
| Normal-vs-Age(81-100Yrs) |
9.014700E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.704200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.062800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.593200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.588400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.319400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.163800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.350700E-04 |
| Classical-VS-Follicular |
2.779000E-01 |
| Classical-VS-Other |
9.433400E-01 |
| Classical-VS-Normal |
1.62669877568078E-12 |
| Tall-VS-Follicular |
2.197500E-04 |
| Tall-VS-Other |
4.359800E-01 |
| Tall-VS-Normal |
8.88178419700125E-15 |
| Follicular-VS-Other |
6.769800E-01 |
| Follicular-VS-Normal |
4.71430000037465E-07 |
| Other-VS-Normal |
5.655400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.21830323607242E-11 |
| Normal-vs-N1 |
1.00186525742174E-12 |
| N0-vs-N1 |
6.820300E-03 |
|
|
